Related Experiment Videos
Cloning and characterization of cDNAs encoding beta-tubulin from Dirofilaria immitis and Onchocerca volvulus
T G Geary1, S C Nulf, S J Alexander-Bowman
1Animal Health Discovery Research, Pharmacia & Upjohn, Kalamazoo, Michigan 49007, USA.
Abstract:
Beta-Tubulin is the target for the benzimidazole anthelmintics. Unfortunately, none of these drugs is clinically useful against adult filariae. However, beta-tubulin has been shown to be a target for antibody-based toxicity to Brugia pahangi. We cloned and characterized cDNAs encoding beta-tubulin from 2 filariae, Dirofilaria immitis and Onchocerca volvulus, to explore possible explanations for benzimidazole insensitivity among adult filariae and the likelihood that epitopes of beta-tubulin could be used as antigens for a broad-spectrum filarial vaccine. The proteins predicted by these cDNAs were almost identical to the beta-tubulin previously reported from B. pahangi but were less similar to a beta-tubulin cDNA from Onchocerca gibsoni. We cloned the genomic locus for the O. volvulus beta-tubulin cDNA and compared its organization to the reported genomic loci for beta-tubulin in B. pahangi and O. gibsoni. The comparison reinforces the conclusion that the published O. gibsoni gene is in a different family, possibly the beta2 family previously described in B. pahangi. The substitution of tyr for phe at position 200 of beta-tubulin is associated with benzimidazole resistance. All 4 filarial beta-tubulins are predicted to encode phe at this position, suggesting that filarial beta-tubulin is not inherently insensitive to the benzimidazoles. A monoclonal antibody that recognizes the COOH terminus of B. pahangi beta-tubulin is lethal to this parasite in culture. The COOH terminal region is the most variable among the different isotypes of beta-tubulin and distinguishes mammalian from nematode tubulins. This region is highly conserved in 3 of the filarial beta-tubulins.
Insights
Benzimidazole anthelmintics target beta-tubulin but are ineffective against adult filariae. Research suggests filarial beta-tubulin is not inherently resistant, opening avenues for new vaccines.
Area of Science:
- Parasitology
- Molecular Biology
- Drug Discovery
Background:
- Benzimidazole anthelmintics target beta-tubulin, but their efficacy against adult filariae is limited.
- Beta-tubulin is a potential target for antibody-based toxicity in filarial parasites.
- Understanding beta-tubulin's role is crucial for developing effective filarial treatments and vaccines.
Purpose of the Study:
- To clone and characterize beta-tubulin cDNAs from Dirofilaria immitis and Onchocerca volvulus.
- To investigate the reasons behind benzimidazole insensitivity in adult filariae.
- To assess the potential of beta-tubulin epitopes as antigens for a broad-spectrum filarial vaccine.
Main Methods:
- Cloning and characterization of beta-tubulin cDNAs from Dirofilaria immitis and Onchocerca volvulus.
- Genomic locus analysis of Onchocerca volvulus beta-tubulin.
- Comparison of beta-tubulin sequences and genomic organization across different filarial species.
Main Results:
- Filarial beta-tubulin proteins are highly similar to each other but distinct from some previously reported sequences.
- Genomic organization comparisons suggest a potential misclassification of a previously reported beta-tubulin gene.
- All analyzed filarial beta-tubulins encode phenylalanine at position 200, a site not associated with benzimidazole resistance.
- The COOH-terminal region of filarial beta-tubulins is conserved and recognized by a lethal monoclonal antibody.
Conclusions:
- Filarial beta-tubulin is likely not inherently insensitive to benzimidazoles.
- The COOH-terminal region of beta-tubulin presents a conserved target for antibody-based therapies.
- Beta-tubulin epitopes hold promise for developing a broad-spectrum filarial vaccine.